Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage

Market Focus08-06

On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB bispecific antibody Opamtistomig has successfully completed the safety run-in period evaluation and entered the expansion stage of its Phase II clinical study for first-line treatment of hepatocellular carcinoma (HCC).

According to the company's disclosure, the expansion milestone was reached following expert review of safety data. HCC is characterized by insidious onset, with fewer than 30% of patients eligible for curative treatment at initial diagnosis, underscoring the critical role of systemic anti-tumor therapy for intermediate-to-advanced cases. This progress follows a series of positive developments for the company's core pipeline, including IND approval for metastatic colorectal cancer granted on August 3, priority review designation for extrapulmonary neuroendocrine carcinoma in July, and six research results selected for presentation at ESMO 2026, including two highest-tier oral presentations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161568880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 10:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161568880","market":"hk","top_or_hot":-1,"title":"Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage","media":"Market Focus","content":"<p><p>On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB bispecific antibody Opamtistomig has successfully completed the safety run-in period evaluation and entered the expansion stage of its Phase II clinical study for first-line treatment of hepatocellular carcinoma (HCC).</p><p>According to the company's disclosure, the expansion milestone was reached following expert review of safety data. HCC is characterized by insidious onset, with fewer than 30% of patients eligible for curative treatment at initial diagnosis, underscoring the critical role of systemic anti-tumor therapy for intermediate-to-advanced cases. This progress follows a series of positive developments for the company's core pipeline, including IND approval for metastatic colorectal cancer granted on August 3, priority review designation for extrapulmonary neuroendocrine carcinoma in July, and six research results selected for presentation at ESMO 2026, including two highest-tier oral presentations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜LEADS BIOLABS-B Rises 5.34% in Regular Trading, Phase II HCC Study Advances to Expansion Stage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-06 10:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB bispecific antibody Opamtistomig has successfully completed the safety run-in period evaluation and entered the expansion stage of its Phase II clinical study for first-line treatment of hepatocellular carcinoma (HCC).</p><p>According to the company's disclosure, the expansion milestone was reached following expert review of safety data. HCC is characterized by insidious onset, with fewer than 30% of patients eligible for curative treatment at initial diagnosis, underscoring the critical role of systemic anti-tumor therapy for intermediate-to-advanced cases. This progress follows a series of positive developments for the company's core pipeline, including IND approval for metastatic colorectal cancer granted on August 3, priority review designation for extrapulmonary neuroendocrine carcinoma in July, and six research results selected for presentation at ESMO 2026, including two highest-tier oral presentations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1161568880","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161568880","pubTimestamp":1785984951,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"走势提醒|LEADS BIOLABS-B常规交易涨5.34%，II期HCC研究进展至扩展阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB bispecific antibody Opamtistomig has successfully completed the safety run-in period evaluation and entered the expansion stage of its Phase II clinical study for first-line treatment of hepatocellular carcinoma (HCC).According to the company's disclosure, the expansion milestone was reached following expert review of safety data. HCC is characterized by insidious onset, with fewer than 30% of patients eligible for curative treatment at initial diagnosis, underscoring the critical role of systemic anti-tumor therapy for intermediate-to-advanced cases. This progress follows a series of positive developments for the company's core pipeline, including IND approval for metastatic colorectal cancer granted on August 3, priority review designation for extrapulmonary neuroendocrine carcinoma in July, and six research results selected for presentation at ESMO 2026, including two highest-tier oral presentations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161568880","isCrawlerRequest":true}